Benitec Biopharma

Apr 17, 2020

Visiongain Report: The Gene Therapy Market is Projected to Grow at a CAGR of 32% in the First Half of the Forecast Period

Oct 31, 2019

Appendix 4C: Quarterly Cash Flow Report

Oct 14, 2019

Global RNA Interference (RNAi) Industry

Sep 16, 2019

Benitec Biopharma Provides Update on BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Program

Aug 13, 2019

RNAi Technologies Market 2019, Industry Analysis, Competitors Strategy, Trends and Demands, Key Applications, Forecast To 2025

Jul 31, 2019

ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report

Jun 06, 2019

Update on Oculopharyngeal Muscular Dystrophy Program

Sep 19, 2018

Benitec Biopharma Announces the Appointment of Gregory R. Reyes, M.D., Ph.D. as Senior Scientific Advisor

Jul 08, 2018

Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant

Jun 12, 2018

Gene Therapy R&D and Revenue Forecasts 2018-2028 - Visiongain Report

May 15, 2018

Benitec to present OPMD data at the American Society of Gene and Cell Therapy Meeting

May 03, 2018

Benitec to Host Investor Webinar on the Company's Oculopharyngeal Muscular Dystrophy (OPMD) Program